Jacob Chacko Sells 53,001 Shares of Oric Pharmaceuticals (NASDAQ:ORIC) Stock

Oric Pharmaceuticals, Inc. (NASDAQ:ORIC) CEO Jacob Chacko sold 53,001 shares of the stock in a transaction dated Wednesday, October 1st. The stock was sold at an average price of $12.05, for a total value of $638,662.05. Following the sale, the chief executive officer directly owned 568,880 shares in the company, valued at $6,855,004. This represents a 8.52% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Jacob Chacko also recently made the following trade(s):

• On Tuesday, September 30th, Jacob Chacko sold 34,538 shares of Oric Pharmaceuticals stock. The shares were sold at an average price of $12.01, for a total value of $414,801.38.
• On Monday, September 22nd, Jacob Chacko sold 125,000 shares of Oric Pharmaceuticals stock. The stock was sold at an average price of $10.80, for a total transaction of $1,350,000.00.

Oric Pharmaceuticals Stock Up 2.1%

Shares of Oric Pharmaceuticals stock opened at $11.56 on Friday. The firm has a market cap of $1.12 billion, a PE ratio of -6.12 and a beta of 1.68. Oric Pharmaceuticals, Inc. has a twelve month low of $3.90 and a twelve month high of $14.67. The business has a 50-day moving average price of $10.39 and a 200 day moving average price of $8.51.

Oric Pharmaceuticals (NASDAQ:ORIC) last released its earnings results on Tuesday, August 12th. The company reported ($0.47) EPS for the quarter, missing analysts’ consensus estimates of ($0.46) by ($0.01). On average, sell-side analysts expect that Oric Pharmaceuticals, Inc. will post -2.17 EPS for the current year.

Institutional Trading of Oric Pharmaceuticals

Institutional investors and hedge funds have recently made changes to their positions in the company. Nisa Investment Advisors LLC boosted its position in shares of Oric Pharmaceuticals by 17,300.0% in the 2nd quarter. Nisa Investment Advisors LLC now owns 2,436 shares of the company’s stock valued at $25,000 after purchasing an additional 2,422 shares during the period. ANTIPODES PARTNERS Ltd lifted its stake in Oric Pharmaceuticals by 35.9% in the second quarter. ANTIPODES PARTNERS Ltd now owns 5,194 shares of the company’s stock valued at $53,000 after buying an additional 1,372 shares during the last quarter. Arizona State Retirement System acquired a new stake in shares of Oric Pharmaceuticals in the first quarter valued at approximately $56,000. Hsbc Holdings PLC purchased a new position in shares of Oric Pharmaceuticals during the first quarter worth approximately $102,000. Finally, Legato Capital Management LLC acquired a new position in shares of Oric Pharmaceuticals in the 1st quarter valued at $109,000. 95.05% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on the company. LADENBURG THALM/SH SH started coverage on Oric Pharmaceuticals in a research note on Tuesday, July 8th. They set a “buy” rating and a $15.00 target price for the company. JPMorgan Chase & Co. reduced their price target on Oric Pharmaceuticals from $20.00 to $17.00 and set an “overweight” rating on the stock in a research report on Thursday, August 14th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Oric Pharmaceuticals in a research report on Saturday, September 27th. HC Wainwright decreased their target price on Oric Pharmaceuticals from $22.00 to $19.00 and set a “buy” rating for the company in a research note on Thursday, August 14th. Finally, Zacks Research upgraded shares of Oric Pharmaceuticals to a “hold” rating in a research note on Tuesday, August 12th. Eight investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $17.29.

Oric Pharmaceuticals Company Profile

ORIC Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, which is designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study; and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, currently under Phase 1b study, being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens.